Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells $12,602.34 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Namandje Bumpus sold 3,963 shares of the firm’s stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $3.18, for a total value of $12,602.34. Following the transaction, the director owned 127,632 shares in the company, valued at approximately $405,869.76. This represents a 3.01% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Namandje Bumpus also recently made the following trade(s):

• On Wednesday, June 3rd, Namandje Bumpus sold 4,386 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $3.54, for a total value of $15,526.44.

Recursion Pharmaceuticals Stock Down 1.5%

Recursion Pharmaceuticals stock traded down $0.05 during midday trading on Monday, hitting $3.18. 14,388,337 shares of the company’s stock were exchanged, compared to its average volume of 17,503,381. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.47 and a current ratio of 5.47. Recursion Pharmaceuticals, Inc. has a 12 month low of $2.77 and a 12 month high of $7.18. The firm has a 50-day moving average of $3.32 and a two-hundred day moving average of $3.74. The company has a market cap of $1.69 billion, a PE ratio of -2.65 and a beta of 1.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative net margin of 842.95% and a negative return on equity of 54.33%. The business had revenue of $6.47 million during the quarter, compared to analyst estimates of $15.78 million. During the same quarter in the previous year, the business posted ($0.50) EPS. The company’s quarterly revenue was down 56.8% compared to the same quarter last year. As a group, analysts expect that Recursion Pharmaceuticals, Inc. will post -0.99 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several institutional investors have recently bought and sold shares of the company. International Assets Investment Management LLC purchased a new position in Recursion Pharmaceuticals in the 4th quarter worth $31,000. Integral Investment Advisors Inc. purchased a new stake in Recursion Pharmaceuticals during the 1st quarter valued at about $39,000. Sequoia Financial Advisors LLC acquired a new position in shares of Recursion Pharmaceuticals in the fourth quarter valued at about $41,000. MQS Management LLC acquired a new position in shares of Recursion Pharmaceuticals in the first quarter valued at about $41,000. Finally, Allworth Financial LP raised its stake in shares of Recursion Pharmaceuticals by 85.6% in the third quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock worth $47,000 after purchasing an additional 4,403 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Tuesday, April 21st. JPMorgan Chase & Co. cut their price target on Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a report on Thursday, April 30th. Bank of America reduced their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating for the company in a research report on Wednesday, February 25th. Morgan Stanley upped their price objective on Recursion Pharmaceuticals from $5.00 to $5.50 and gave the stock an “equal weight” rating in a research note on Thursday, May 14th. Finally, Wall Street Zen lowered Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $8.10.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.